26 Apr New Drug Combination May Delay Brain Metastases in HER2+ Breast Cancer

Posted at 11:19h in Author Interviews, Breast Cancer, JAMA by

MedicalResearch.com Interview with:

Ahmad Awada, MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles Bruxelles, Belgium

Dr. Ahmad Awada

Ahmad Awada, MD, PhD
Medical Oncology Clinic
Institut Jules Bordet
Université Libre de Bruxelles
Bruxelles, Belgium

MedicalResearch.com: What is the background for this study? What are the main findings?
Dr. Awada: This Study compared, in a randomized fashion, paclitaxel + trastuzumab to paclitaxel + neratinib in the first line setting of metastatic breast cancer. All outcome endpoints (PFS, OS, ORR) were similar.

In addition, paclitaxel + neratinib delayed the appearance and decreased the incidence of central nervous system (CNS) events (secondary end point)

MedicalResearch.com: What should clinicians and patients take away from your report?

Dr. Awada:  Paclitaxel + neratinib is as effective as paclitaxel + trastuzumab.

The data suggested that neratinib could influence the pattern of CNS events in HER2+ metastatic breast cancer. These emerging data on CNS events are under validation in the NALA trial.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Dr. Awada: Ongoing clinical trials and early reports from the early setting will help to define the role of neratinib in the therapeutic algorithms of HER2+ breast cancer.

MedicalResearch.com: Is there anything else you would like to add?

Dr. Awada:  Diarrhea, which is a significant side effect of neratinib, could be reduced by intensive and early loperamide therapy.

MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.

Citation:

Ahmad Awada, Ramon Colomer, Kenichi Inoue, Igor Bondarenko, Rajendra A. Badwe, Georgia Demetriou, Soo-Chin Lee, Ajay O. Mehta, Sung-Bae Kim, Thomas Bachelot, Chanchal Goswami, Suryanarayan Deo, Ron Bose, Alvin Wong, Feng Xu, Bin Yao, Richard Bryce, Lisa A. Carey.Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer. JAMA Oncology, 2016; DOI: 1001/jamaoncol.2016.0237

 

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on MedicalResearch.com

 

 

 

Last Updated on April 26, 2016 by Marie Benz MD FAAD

269